Luvixasertib (CFI-402257) is an inhibitor of threonine tyrosine kinase (TTK) with IC50 of 1.7 nM and Ki of 0.1 nM, respectively. It is a potential therapeutic for treating hepatocellular carcinoma that works directly by inhibiting cell-cycle checkpoints in cancer cells and indirectly by mobilizing immune cells from the tumor microenvironment.

INT-777 (S-EMCA) is a potent and selective agonist of TGR5(GPCR19) with EC50 of 0.18 μM, 3.9 μM and 1.45 μM for TGR5, TGR5(N76A) and TGR5(Y89F) respectively.

Phalloidin is a mushroom-derived toxin which can be used to label F-actin of the cytoskeleton with fluorochrome .

Plicamycin (Mithramycin A) a selective inhibitor of Sp1, is a natural polycyclic aromatic polyketide isolated from Streptomyces strains. It binds to GC-rich DNA sequences, displacing Sp1 transcription factor from oncogene promoters, inhibiting their expression, with anti-tumor and neuroprotective effects.

Voruciclib(P1446A-05) is a small molecule flavone derivative, a pan inhibitor of CDK with Ki’s of 0.626 nM-9.1nM, that potently targets CDK9, represses expression of MCL-1 and leads to tumor cell apoptosis and tumor growth inhibition in multiple models of diffuse large B-cell lymphoma (DLBCL).

Mavoglurant (AFQ056) is a structurally selective, non-competitive antagonist of mGlu5 receptor with an IC50 of 30 nM. It exhibits efficacy in treatment of L-dopa induced dyskinesia in Parkinson’s disease and Fragile X syndrome.